表紙:ポイントオブケア検査の世界市場 (2021-2027年):市場予測 (製品・技術・処方区分・用途・エンドユーザー別)・COVID-19の影響・地域的展望・用途の潜在性・価格動向・市場シェア
市場調査レポート
商品コード
1036823

ポイントオブケア検査の世界市場 (2021-2027年):市場予測 (製品・技術・処方区分・用途・エンドユーザー別)・COVID-19の影響・地域的展望・用途の潜在性・価格動向・市場シェア

Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 400 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
ポイントオブケア検査の世界市場 (2021-2027年):市場予測 (製品・技術・処方区分・用途・エンドユーザー別)・COVID-19の影響・地域的展望・用途の潜在性・価格動向・市場シェア
出版日: 2021年11月12日
発行: Global Market Insights Inc.
ページ情報: 英文 400 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

POC (ポイントオブケア) 検査の市場は、感染症の世界的流行の拡大により、2027年にかけて大幅な成長を示すと予測されています。

また、高齢者人口が着実に増加していることも市場の見通しを強くする要因となっています。

製品別で見ると、心血管検査製品の部門が2020年に約30億米ドルの規模を示し、予測期間中も大幅な成長を示すと予測されています。技術別では、バイオセンサーの部門が今後大幅な成長を示し、2027年末には156億米ドル超の規模に成長すると予測されています。

当レポートでは、世界のPOC (ポイントオブケア) 検査の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、イノベーション・持続可能性の情勢、市場規模の推移・予測、製品・技術・処方区分・用途・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 POC (ポイントオブケア) 検査産業の考察

  • 産業の分類
  • 産業情勢
  • 産業への影響要因
    • 成長要因
    • 潜在的リスク&課題
  • 成長の可能性
  • COVID-19:影響分析
  • 価格分析
  • 規制状況
  • 技術情勢
  • 企業シェア分析
  • ポーターの分析
  • 競合情勢
  • PESTEL分析

第4章 POC検査市場:製品別

  • 主要動向
  • グルコースモニタリング
    • ストリップ
    • メーター
    • ランセット
  • 心臓代謝検査製品
    • 心臓マーカー検査製品
    • 血液ガス/電解質検査製品
    • HBA1C検査製品
  • 感染症検査製品
    • インフルエンザ検査製品
    • HIV検査製品
    • C型肝炎検査製品
    • 性感染症 (STD) 検査製品
    • 医療関連感染 (HAI) 検査製品
    • 呼吸器感染症検査製品
    • 熱帯病検査製品
    • その他
  • 凝固検査製品
    • PT/INR検査製品
    • 活性化凝固時間 (ACT/APTT) 検査製品
  • 妊娠・受胎能検査製品
    • 妊娠検査製品
    • 受胎能検査製品
  • 腫瘍/癌マーカー検査製品
  • 尿検査製品
  • コレステロール検査製品
  • 血液検査製品
  • 薬物乱用 (DoA) 検査製品
  • 便潜血検査製品
  • その他

第5章 POC検査市場:技術別

  • 主要動向
  • イムノクロマトグラフィー
  • ディップスティック
  • マイクロフルイディクス
  • 分子診断
  • 免疫学的検査
  • 凝集アッセイ
  • フロースルー
  • 固相
  • バイオセンサー

第6章 POC検査市場:処方区分別

  • 主要動向
  • OTC検査
  • 処方箋ベースの検査

第7章 POC検査市場:用途別

  • 主要動向
  • 心臓代謝検査
  • 感染症検査
  • 腎臓検査
  • 薬物乱用 (DoA) 検査
  • 血糖値検査
  • 妊娠検査
  • 癌バイオマーカー検査
  • その他

第8章 POC検査市場:エンドユーザー別

  • 主要動向
  • 病院
  • 診断センター
  • 研究機関
  • 在宅介護
  • その他

第9章 POC検査市場:地域別

  • 主要動向
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第10章 企業プロファイル

  • 競合ダッシュボード
  • Abaxis, Inc.
  • Abbott Laboratories
  • Accubiotech Co, Ltd.
  • ACON Laboratories, Inc
  • Becton, Dickinson and Company
  • Biolytical Laboratories
  • BioMrieux SA
  • Bio-Rad Laboratories, Inc
  • Danaher Corporation(HemoCue)
  • Dexcom, Inc
  • Dragerwerk Ag & Co
  • LifeScan IP Holdings, LLC
  • Medtronic
  • Meridian Bioscience, Inc
  • Nova Biomedical
  • Orasure Technologies, Inc
  • F Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Sysmex Corporation
  • Trinity Biotech
目次
Product Code: 3086

The point of care testing market is projected to witness sturdy expansion by 2027 due to rising prevalence of infectious diseases across the globe. In addition, industry prospects are also likely to be strengthened by the steadily growing geriatric population.

Point-of-care (POC) testing entails performing a diagnostic test outside of a laboratory that delivers a quick and reliable result, assisting in the management and diagnosis of chronic diseases and acute infections.

According to a May 2021 study published in American Chemical Society, the ongoing COVID-19 pandemic has emphasized the importance of large-scale, rapid, and accurate disease diagnosis through effective point-of-care (POC) molecular diagnostic tests.

Moreover, the COVID-19 point of care diagnostics market is rapidly evolving to accommodate soaring demand for decentralized and low-cost diagnostics around the globe. Subsequently, the proliferation of pathology labs and diagnostic services has propelled product penetration in the market in recent years.

The point of care testing market has been segmented based on application, product, end-use, prescription, technology, and region.

In terms of product, the market has further been divided into fecal occult testing products, glucose monitoring, drug-of-abuse (DoA) testing products, cardiometabolic testing products, hematology testing products, infectious disease testing products, cholesterol testing products, coagulation testing products, urinalysis testing products, pregnancy and fertility testing products, tumor/cancer marker testing products, and other products.

The cardiometabolic testing products segment attained a sizable valuation of around USD 3.0 billion in 2020 and is expected to further amass notable gains over the forecast period.

From the technology perspective, the market has been categorized into biosensors, lateral flow assays, solid phase, dipsticks, flow-through, microfluidics, agglutination assays, molecular diagnostics, and immunoassays. The biosensors segment is slated to grow at a considerable pace through the review timeline and hit a valuation of more than USD 15.6 billion by the end of 2027.

With respect to prescription, the market has been bifurcated into prescription-based testing and OTC testing. The point of care market from the prescription-based testing sub-segment is anticipated to expand at a significant pace of 7.7% through the stipulated timeframe.

On the basis of application, the market has been segregated into cancer biomarker testing, cardiometabolic testing, pregnancy testing, infectious disease testing, blood glucose testing, nephrology testing, drug-of-abuse (DoA) testing, and other applications. In 2020, the blood glucose testing sub-segment held a substantial market share of over 42.2% and is set to observe robust expansion through the analysis timeline.

In terms of end-use, the market has been classified into home-care settings, hospitals, research laboratories, diagnostic centers, and others. The home-care setting sub-segment is estimated to reach a valuation of more than USD 13.4 billion by the end of 2027.

From the regional spectrum, the Latin America point of care testing market accounted for a market share of above 5.7% in 2020 and is likely to showcase a sturdy growth trajectory through 2021-2027.

Meanwhile, the Middle East & Africa point of care testing market is expected to exhibit robust growth of over 8.0% through the assessment period.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definition
  • 1.2 Base estimates & working
    • 1.2.1 North America
    • 1.2.2 Europe
    • 1.2.3 Asia pacific
    • 1.2.4 Latin America
    • 1.2.5 Middle East & Africa
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Point of care testing industry 360 degree synopsis, 2016 - 2027 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Technology trends
    • 2.1.4 Prescription trends
    • 2.1.5 Application trends
    • 2.1.6 End-use trends
    • 2.1.7 Regional trends

Chapter 3 Point of Care Testing Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2016 - 2027
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Upward trend in disease prevalence among developing countries
      • 3.3.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
      • 3.3.1.3 Technological advancements
      • 3.3.1.4 Increasing R&D investment
      • 3.3.1.5 Growing geriatric population base globally
    • 3.3.2 Industry pitfalls and challenges
      • 3.3.2.1 Stringent regulatory framework
      • 3.3.2.2 High cost of product development
  • 3.4 Growth potential analysis
    • 3.4.1 By product
    • 3.4.2 By technology
    • 3.4.3 By prescription
    • 3.4.4 By application
    • 3.4.5 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Pricing analysis, by cardiac markers, 2020
  • 3.7 Regulatory landscape
  • 3.8 Technology landscape
  • 3.9 Company share analysis, 2020
    • 3.9.1 Global market share analysis, 2020
    • 3.9.2 North America
    • 3.9.3 Europe
    • 3.9.4 Asia Pacific
    • 3.9.5 Latin America
    • 3.9.6 Middle East and Africa
  • 3.10 Porter's analysis
  • 3.11 Competitive landscape,2020
    • 3.11.1 Company matrix analysis
  • 3.12 PESTEL analysis

Chapter 4 Point of Care Testing Market, By Product

  • 4.1 Key segment trends
  • 4.2 Glucose monitoring
    • 4.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.2 Strips
      • 4.2.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.3 Meters
      • 4.2.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.2.4 Lancets
      • 4.2.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.3 Cardiometabolic testing products
    • 4.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.2 Cardiac marker testing products
      • 4.3.2.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.2 High-sensitivity troponin I (hsTnl)
        • 4.3.2.2.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.3 Brain natriuretic peptide (BNP)
        • 4.3.2.3.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.4 D-dimer
        • 4.3.2.4.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.5 Creatine kinase-MB (CK-MB)
        • 4.3.2.5.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.6 Myoglobin
        • 4.3.2.6.1 Market size, by region, 2016 - 2027 (USD Million)
      • 4.3.2.7 Others
        • 4.3.2.7.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.3 Blood Gas/Electrolytes testing products
      • 4.3.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.3.4 HBA1C testing products
      • 4.3.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.4 Infectious disease testing products
    • 4.4.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.2 Influenza testing products
      • 4.4.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.3 HIV testing products
      • 4.4.3.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.4 Hepatitis C testing products
      • 4.4.4.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.5 Sexually transmitted disease (STD) testing products
      • 4.4.5.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.6 Healthcare-associated Infection (HAI) testing products
      • 4.4.6.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.7 Respiratory infection testing products
      • 4.4.7.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.8 Tropical disease testing products
      • 4.4.8.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.4.9 Other infectious diseases testing products
      • 4.4.9.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.5 Coagulation testing products
    • 4.5.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.5.2 PT/INR testing products
      • 4.5.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.5.3 Activated clotting time (ACT/APTT) testing products
      • 4.5.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.6 Pregnancy and fertility testing products
    • 4.6.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.6.2 Pregnancy testing products
      • 4.6.2.1 Market size, by region, 2016 - 2027 (USD Million)
    • 4.6.3 Fertility testing products
      • 4.6.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.7 Tumor/Cancer marker testing products
    • 4.7.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.8 Urinalysis testing products
    • 4.8.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.9 Cholesterol testing products
    • 4.9.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.10 Hematology testing products
    • 4.10.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.11 Drug-of-Abuse (DoA) testing products
    • 4.11.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.12 Fecal occult testing products
    • 4.12.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.13 Other products
    • 4.13.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 5 Point of Care Testing Market, By Technology

  • 5.1 Key segment trends
  • 5.2 Lateral flow assays
    • 5.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.3 Dipsticks
    • 5.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.4 Microfluidics
    • 5.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.5 Molecular diagnostics
    • 5.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.6 Immunoassays
    • 5.6.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.7 Agglutination assays
    • 5.7.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.8 Flow-through
    • 5.8.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.9 Solid phase
    • 5.9.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.10 Biosensors
    • 5.10.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 6 Point of Care Testing Market, By Prescription

  • 6.1 Key segment trends
  • 6.2 OTC testing
    • 6.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.3 Prescription-based testing
    • 6.3.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 7 Point of Care Testing Market, By Application

  • 7.1 Key segment trends
  • 7.2 Cardio metabolic testing
    • 7.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.3 Infectious disease testing
    • 7.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.4 Nephrology testing
    • 7.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.5 Drug-of-Abuse (DoA) testing
    • 7.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.6 Blood glucose testing
    • 7.6.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.7 Pregnancy testing
    • 7.7.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.8 Cancer biomarker testing
    • 7.8.1 Market size, by region, 2016 - 2027 (USD Million)
  • 7.9 Other applications
    • 7.9.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 8 Point of Care Testing Market, By End-use

  • 8.1 Key segment trends
  • 8.2 Hospitals
    • 8.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 8.3 Diagnostic centers
    • 8.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 8.4 Research laboratories
    • 8.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 8.5 Home-care settings
    • 8.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 8.6 Others
    • 8.6.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 9 Point of Care Testing Market, By Region

  • 9.1 Key regional trends
  • 9.2 North America
    • 9.2.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.2.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.2.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.2.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.2.2.2.1 Market size, by cardiac marker testing product, 2016 - 2027 (USD Million)
      • 9.2.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.2.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.2.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.2.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.2.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.2.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.2.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.2.7 U.S.
      • 9.2.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.2.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.2.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.2.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.2.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.2.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.2.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.2.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.2.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.2.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.2.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.2.8 Canada
      • 9.2.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.2.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.2.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.2.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.2.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.2.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.2.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.2.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.2.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.2.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.2.8.5 Market size, by end-use, 2016 - 2027 (USD Million)
  • 9.3 Europe
    • 9.3.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.3.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.3.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.3.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.2.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
      • 9.3.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.3.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.3.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.3.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.3.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.3.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.3.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.7 Germany
      • 9.3.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.8 UK
      • 9.3.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.8.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.9 France
      • 9.3.9.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.9.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.9.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.9.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.9.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.9.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.9.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.9.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.9.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.9.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.9.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.10 Spain
      • 9.3.10.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.10.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.10.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.10.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.10.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.10.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.10.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.10.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.10.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.10.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.10.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.3.11 Italy
      • 9.3.11.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.3.11.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.3.11.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.3.11.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.3.11.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.3.11.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.3.11.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.3.11.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.3.11.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.3.11.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.3.11.5 Market size, by end-use, 2016 - 2027 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.4.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.4.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.4.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.2.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
      • 9.4.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.4.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.4.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.4.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.4.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.4.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.4.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.4.7 China
      • 9.4.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.4.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.4.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.4.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.4.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.4.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.4.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.4.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.4.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.4.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.4.8 Japan
      • 9.4.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.4.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.4.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.4.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.4.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.4.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.4.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.4.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.4.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.4.8.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.4.9 India
      • 9.4.9.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.4.9.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.4.9.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.9.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.4.9.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.4.9.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.4.9.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.4.9.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.4.9.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.4.9.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.4.9.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.4.10 Australia
      • 9.4.10.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.4.10.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.4.10.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.4.10.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.4.10.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.4.10.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.4.10.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.4.10.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.4.10.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.4.10.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.4.10.5 Market size, by end-use, 2016 - 2027 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.5.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.5.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.5.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.5.2.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
      • 9.5.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.5.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.5.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.5.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.5.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.5.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.5.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.5.7 Brazil
      • 9.5.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.5.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.5.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.5.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.5.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.5.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.5.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.5.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.5.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.5.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.5.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.5.8 Mexico
      • 9.5.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.5.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.5.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.5.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.5.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.5.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.5.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.5.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.5.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.5.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.5.8.5 Market size, by end-use, 2016 - 2027 (USD Million)
  • 9.6 Middle East and Africa
    • 9.6.1 Market size, by country, 2016 - 2027 (USD Million)
    • 9.6.2 Market size, by product, 2016 - 2027 (USD Million)
      • 9.6.2.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
      • 9.6.2.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.6.2.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
      • 9.6.2.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
      • 9.6.2.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
      • 9.6.2.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
    • 9.6.3 Market size, by technology, 2016 - 2027 (USD Million)
    • 9.6.4 Market size, by prescription, 2016 - 2027 (USD Million)
    • 9.6.5 Market size, by application, 2016 - 2027 (USD Million)
    • 9.6.6 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.6.7 South Africa
      • 9.6.7.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.6.7.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.6.7.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.6.7.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.6.7.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.6.7.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.6.7.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.6.7.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.6.7.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.6.7.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.6.7.5 Market size, by end-use, 2016 - 2027 (USD Million)
    • 9.6.8 Saudi Arabia
      • 9.6.8.1 Market size, by product, 2016 - 2027 (USD Million)
        • 9.6.8.1.1 Market size, by glucose monitoring, 2016 - 2027 (USD Million)
        • 9.6.8.1.2 Market size, by cardiometabolic testing products, 2016 - 2027 (USD Million)
        • 9.6.8.1.2.1 Market size, by cardiac marker testing products, 2016-2027 (USD Million)
        • 9.6.8.1.3 Market size, by infectious disease testing products, 2016 - 2027 (USD Million)
        • 9.6.8.1.4 Market size, by coagulation testing products, 2016 - 2027 (USD Million)
        • 9.6.8.1.5 Market size, by pregnancy and fertility testing products, 2016 - 2027 (USD Million)
      • 9.6.8.2 Market size, by technology, 2016 - 2027 (USD Million)
      • 9.6.8.3 Market size, by prescription, 2016 - 2027 (USD Million)
      • 9.6.8.4 Market size, by application, 2016 - 2027 (USD Million)
      • 9.6.8.5 Market size, by end-use, 2016 - 2027 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Competitive dashboard
  • 10.2 Abaxis, Inc.
    • 10.2.1 Business overview
    • 10.2.2 Financial data
    • 10.2.3 Product landscape
    • 10.2.4 Strategic outlook
    • 10.2.5 SWOT analysis
  • 10.3 Abbott Laboratories
    • 10.3.1 Business overview
    • 10.3.2 Financial data
    • 10.3.3 Product landscape
    • 10.3.4 Strategic outlook
    • 10.3.5 SWOT analysis
  • 10.4 Accubiotech Co, Ltd.
    • 10.4.1 Business overview
    • 10.4.2 Financial data
    • 10.4.3 Product landscape
    • 10.4.4 Strategic outlook
    • 10.4.5 SWOT analysis
  • 10.5 ACON Laboratories, Inc
    • 10.5.1 Business overview
    • 10.5.2 Financial data
    • 10.5.3 Product landscape
    • 10.5.4 Strategic outlook
    • 10.5.5 SWOT analysis
  • 10.6 Becton, Dickinson and Company
    • 10.6.1 Business overview
    • 10.6.2 Financial data
    • 10.6.3 Product landscape
    • 10.6.4 Strategic outlook
    • 10.6.5 SWOT analysis
  • 10.7 Biolytical Laboratories
    • 10.7.1 Business overview
    • 10.7.2 Financial data
    • 10.7.3 Product landscape
    • 10.7.4 Strategic outlook
    • 10.7.5 SWOT analysis
  • 10.8 BioMrieux SA
    • 10.8.1 Business overview
    • 10.8.2 Financial data
    • 10.8.3 Product landscape
    • 10.8.4 Strategic outlook
    • 10.8.5 SWOT analysis
  • 10.9 Bio-Rad Laboratories, Inc
    • 10.9.1 Business overview
    • 10.9.2 Financial data
    • 10.9.3 Product landscape
    • 10.9.4 Strategic outlook
    • 10.9.5 SWOT analysis
  • 10.10 Danaher Corporation (HemoCue)
    • 10.10.1 Business overview
    • 10.10.2 Financial data
    • 10.10.3 Product landscape
    • 10.10.4 Strategic outlook
    • 10.10.5 SWOT analysis
  • 10.11 Dexcom, Inc
    • 10.11.1 Business overview
    • 10.11.2 Financial data
    • 10.11.3 Product landscape
    • 10.11.4 Strategic outlook
    • 10.11.5 SWOT analysis
  • 10.12 Dragerwerk Ag & Co
    • 10.12.1 Business overview
    • 10.12.2 Financial data
    • 10.12.3 Product landscape
    • 10.12.4 Strategic outlook
    • 10.12.5 SWOT analysis
  • 10.13 LifeScan IP Holdings, LLC
    • 10.13.1 Business overview
    • 10.13.2 Financial data
    • 10.13.3 Product landscape
    • 10.13.4 Strategic outlook
    • 10.13.5 SWOT analysis
  • 10.14 Medtronic
    • 10.14.1 Business overview
    • 10.14.2 Financial data
    • 10.14.3 Product landscape
    • 10.14.4 Strategic outlook
    • 10.14.5 SWOT analysis
  • 10.15 Meridian Bioscience, Inc
    • 10.15.1 Business overview
    • 10.15.2 Financial data
    • 10.15.3 Product landscape
    • 10.15.4 Strategic outlook
    • 10.15.5 SWOT analysis
  • 10.16 Nova Biomedical
    • 10.16.1 Business overview
    • 10.16.2 Financial data
    • 10.16.3 Product landscape
    • 10.16.4 Strategic outlook
    • 10.16.5 SWOT analysis
  • 10.17 Orasure Technologies, Inc
    • 10.17.1 Business overview
    • 10.17.2 Financial data
    • 10.17.3 Product landscape
    • 10.17.4 Strategic outlook
    • 10.17.5 SWOT analysis
  • 10.18 F Hoffmann-La Roche Ltd
    • 10.18.1 Business overview
    • 10.18.2 Financial data
    • 10.18.3 Product landscape
    • 10.18.4 Strategic outlook
    • 10.18.5 SWOT analysis
  • 10.19 Siemens Healthineers
    • 10.19.1 Business overview
    • 10.19.2 Financial data
    • 10.19.3 Product landscape
    • 10.19.4 Strategic outlook
    • 10.19.5 SWOT analysis
  • 10.20 Sysmex Corporation
    • 10.20.1 Business overview
    • 10.20.2 Financial data
    • 10.20.3 Product landscape
    • 10.20.4 Strategic outlook
    • 10.20.5 SWOT analysis
  • 10.21 Trinity Biotech
    • 10.21.1 Business overview
    • 10.21.2 Financial data
    • 10.21.3 Product landscape
    • 10.21.4 Strategic outlook
    • 10.21.5 SWOT analysis